Diagnostic Efficacy of Serum Asialo α1-Acid Glycoprotein Levels for Advanced Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Compared to That in Healthy Subjects: A Prospective Study
Background: Serum asialo α1-acid gycoprotein (AsAGP) is a novel biomarker specific to liver fibrosis. Aim: To evaluate the diagnostic efficacy of serum AsAGP levels in classifying the severity of liver fibrosis and differentiating liver cirrhosis (LC) in patients with chronic hepatitis B (CHB) from...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical medicine 2023-01, Vol.12 (2), p.712 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 2 |
| container_start_page | 712 |
| container_title | Journal of clinical medicine |
| container_volume | 12 |
| creator | Lee, Yoonseok Bae, Seryun Kim, Ji Hoon Kwak, Minjung Jeon, So Yeon Kim, Taehyung Yim, Sun Young Lee, Young-Sun Jung, Young Kul Seo, Yeon Seok Yim, Hyung Joon Yeon, Jong Eun Byun, Kwan Soo |
| description | Background: Serum asialo α1-acid gycoprotein (AsAGP) is a novel biomarker specific to liver fibrosis. Aim: To evaluate the diagnostic efficacy of serum AsAGP levels in classifying the severity of liver fibrosis and differentiating liver cirrhosis (LC) in patients with chronic hepatitis B (CHB) from healthy controls. Methods: Overall, 206 subjects were prospectively enrolled. LC was diagnosed based on liver stiffness levels (>11 kPa) measured using transient elastography. Serum AsAGP levels were measured using an antibody-lectin sandwich immunoassay. We investigated the diagnostic performance by comparing serum AsAGP levels among healthy control, CHB, and CHB with LC groups. Sensitivity, specificity, and optimal AsAGP cut-off values were also calculated. Results: Serum AsAGP levels were significantly different between healthy controls, CHB patients, and CHB patients with LC (1.04 ± 0.31 µg/mL, 1.12 ± 0.34 µg/mL, 1.51 ± 0.43 µg/mL respectively; p < 0.001). Serum AsAGP levels positively correlated with liver stiffness (r = 0.46, p < 0.001). AUROC of healthy control versus CHB with LC was 0.821 (p < 0.001, optimal cut-off 1.036 µg/mL). AUROC of healthy control versus CHB was 0.624 (p = 0.049, optimal cut-off level 0.934 µg/mL). AUROC of CHB versus CHB with LC was 0.765, (p < 0.001, optimal cut-off 1.260 µg/mL). Conclusions: Serum AsAGP levels in CHB patients with LC were significantly higher than those in healthy controls and CHB patients. AsAGP levels showed good diagnostic performance in predicting advanced fibrosis and cirrhosis, which suggests a potential role as a biomarker for predicting the progression of liver disease in CHB. |
| doi_str_mv | 10.3390/jcm12020712 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9863335</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2767221881</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-b88e4b1ac931d3105a06cd6ecd493289e2a8275d541e9d22de5b09dfc8bb2cf43</originalsourceid><addsrcrecordid>eNpdkk1v1DAQhiMEolXpiTsaiQsSWvBHPhwOSOnSdpFWotKWc-TYk8arJA62s2h_Fj-DC78JLy3Vgi_jsZ9537E1SfKSknecl-T9Vg2UEUYKyp4kpzEWC8IFf3q0P0nOvd-SuIRIGS2eJyc8z4ssT8lp8vOTkXej9cEouGxbo6Tag21hg24eoPJG9hZ-_aCLShkN1_1e2cnZgGaENe6w99BaB5XeyVGhhrXZoYMr0zjrjQc5alga57o_Way5kcHgGDx8N6GDZefsGI1XOMXzEJELWNphki5KBQu3nQyHqhXKPnR72MzNFlXwH6CCm-gwxSQawibMev8iedbK3uP5QzxLvl5d3i5Xi_WX68_Lar1QKSnDohEC04ZKVXKqOSWZJLnSOSqdlpyJEpkUrMh0llIsNWMas4aUulWiaZhqU36WfLzXneZmQK3ic5zs68mZQbp9baWp_70ZTVff2V1dipxznkWBNw8Czn6b0Yd6MF5h38sR7exrVuSCsawoD16v_0O3dnZjfN6BKhijQtBIvb2nVPwT77B9bIaS-jAl9dGURPrVcf-P7N-Z4L8BJmq8HQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2767221881</pqid></control><display><type>article</type><title>Diagnostic Efficacy of Serum Asialo α1-Acid Glycoprotein Levels for Advanced Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Compared to That in Healthy Subjects: A Prospective Study</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><creator>Lee, Yoonseok ; Bae, Seryun ; Kim, Ji Hoon ; Kwak, Minjung ; Jeon, So Yeon ; Kim, Taehyung ; Yim, Sun Young ; Lee, Young-Sun ; Jung, Young Kul ; Seo, Yeon Seok ; Yim, Hyung Joon ; Yeon, Jong Eun ; Byun, Kwan Soo</creator><creatorcontrib>Lee, Yoonseok ; Bae, Seryun ; Kim, Ji Hoon ; Kwak, Minjung ; Jeon, So Yeon ; Kim, Taehyung ; Yim, Sun Young ; Lee, Young-Sun ; Jung, Young Kul ; Seo, Yeon Seok ; Yim, Hyung Joon ; Yeon, Jong Eun ; Byun, Kwan Soo</creatorcontrib><description>Background: Serum asialo α1-acid gycoprotein (AsAGP) is a novel biomarker specific to liver fibrosis. Aim: To evaluate the diagnostic efficacy of serum AsAGP levels in classifying the severity of liver fibrosis and differentiating liver cirrhosis (LC) in patients with chronic hepatitis B (CHB) from healthy controls. Methods: Overall, 206 subjects were prospectively enrolled. LC was diagnosed based on liver stiffness levels (>11 kPa) measured using transient elastography. Serum AsAGP levels were measured using an antibody-lectin sandwich immunoassay. We investigated the diagnostic performance by comparing serum AsAGP levels among healthy control, CHB, and CHB with LC groups. Sensitivity, specificity, and optimal AsAGP cut-off values were also calculated. Results: Serum AsAGP levels were significantly different between healthy controls, CHB patients, and CHB patients with LC (1.04 ± 0.31 µg/mL, 1.12 ± 0.34 µg/mL, 1.51 ± 0.43 µg/mL respectively; p < 0.001). Serum AsAGP levels positively correlated with liver stiffness (r = 0.46, p < 0.001). AUROC of healthy control versus CHB with LC was 0.821 (p < 0.001, optimal cut-off 1.036 µg/mL). AUROC of healthy control versus CHB was 0.624 (p = 0.049, optimal cut-off level 0.934 µg/mL). AUROC of CHB versus CHB with LC was 0.765, (p < 0.001, optimal cut-off 1.260 µg/mL). Conclusions: Serum AsAGP levels in CHB patients with LC were significantly higher than those in healthy controls and CHB patients. AsAGP levels showed good diagnostic performance in predicting advanced fibrosis and cirrhosis, which suggests a potential role as a biomarker for predicting the progression of liver disease in CHB.</description><identifier>ISSN: 2077-0383</identifier><identifier>EISSN: 2077-0383</identifier><identifier>DOI: 10.3390/jcm12020712</identifier><identifier>PMID: 36675640</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Accuracy ; Acids ; Biomarkers ; Biopsy ; Clinical medicine ; Diabetes ; Glycoproteins ; Hepatitis B ; Hypertension ; Laboratories ; Liver cancer ; Liver cirrhosis ; Liver diseases ; Patients</subject><ispartof>Journal of clinical medicine, 2023-01, Vol.12 (2), p.712</ispartof><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c409t-b88e4b1ac931d3105a06cd6ecd493289e2a8275d541e9d22de5b09dfc8bb2cf43</citedby><cites>FETCH-LOGICAL-c409t-b88e4b1ac931d3105a06cd6ecd493289e2a8275d541e9d22de5b09dfc8bb2cf43</cites><orcidid>0000-0001-6396-0859 ; 0000-0002-0510-7371 ; 0000-0002-6566-1382 ; 0000-0002-7747-4293 ; 0000-0001-5493-3592 ; 0000-0001-7346-5974 ; 0000-0003-3924-0434</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863335/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863335/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,725,778,782,883,27911,27912,53778,53780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36675640$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Yoonseok</creatorcontrib><creatorcontrib>Bae, Seryun</creatorcontrib><creatorcontrib>Kim, Ji Hoon</creatorcontrib><creatorcontrib>Kwak, Minjung</creatorcontrib><creatorcontrib>Jeon, So Yeon</creatorcontrib><creatorcontrib>Kim, Taehyung</creatorcontrib><creatorcontrib>Yim, Sun Young</creatorcontrib><creatorcontrib>Lee, Young-Sun</creatorcontrib><creatorcontrib>Jung, Young Kul</creatorcontrib><creatorcontrib>Seo, Yeon Seok</creatorcontrib><creatorcontrib>Yim, Hyung Joon</creatorcontrib><creatorcontrib>Yeon, Jong Eun</creatorcontrib><creatorcontrib>Byun, Kwan Soo</creatorcontrib><title>Diagnostic Efficacy of Serum Asialo α1-Acid Glycoprotein Levels for Advanced Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Compared to That in Healthy Subjects: A Prospective Study</title><title>Journal of clinical medicine</title><addtitle>J Clin Med</addtitle><description>Background: Serum asialo α1-acid gycoprotein (AsAGP) is a novel biomarker specific to liver fibrosis. Aim: To evaluate the diagnostic efficacy of serum AsAGP levels in classifying the severity of liver fibrosis and differentiating liver cirrhosis (LC) in patients with chronic hepatitis B (CHB) from healthy controls. Methods: Overall, 206 subjects were prospectively enrolled. LC was diagnosed based on liver stiffness levels (>11 kPa) measured using transient elastography. Serum AsAGP levels were measured using an antibody-lectin sandwich immunoassay. We investigated the diagnostic performance by comparing serum AsAGP levels among healthy control, CHB, and CHB with LC groups. Sensitivity, specificity, and optimal AsAGP cut-off values were also calculated. Results: Serum AsAGP levels were significantly different between healthy controls, CHB patients, and CHB patients with LC (1.04 ± 0.31 µg/mL, 1.12 ± 0.34 µg/mL, 1.51 ± 0.43 µg/mL respectively; p < 0.001). Serum AsAGP levels positively correlated with liver stiffness (r = 0.46, p < 0.001). AUROC of healthy control versus CHB with LC was 0.821 (p < 0.001, optimal cut-off 1.036 µg/mL). AUROC of healthy control versus CHB was 0.624 (p = 0.049, optimal cut-off level 0.934 µg/mL). AUROC of CHB versus CHB with LC was 0.765, (p < 0.001, optimal cut-off 1.260 µg/mL). Conclusions: Serum AsAGP levels in CHB patients with LC were significantly higher than those in healthy controls and CHB patients. AsAGP levels showed good diagnostic performance in predicting advanced fibrosis and cirrhosis, which suggests a potential role as a biomarker for predicting the progression of liver disease in CHB.</description><subject>Accuracy</subject><subject>Acids</subject><subject>Biomarkers</subject><subject>Biopsy</subject><subject>Clinical medicine</subject><subject>Diabetes</subject><subject>Glycoproteins</subject><subject>Hepatitis B</subject><subject>Hypertension</subject><subject>Laboratories</subject><subject>Liver cancer</subject><subject>Liver cirrhosis</subject><subject>Liver diseases</subject><subject>Patients</subject><issn>2077-0383</issn><issn>2077-0383</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdkk1v1DAQhiMEolXpiTsaiQsSWvBHPhwOSOnSdpFWotKWc-TYk8arJA62s2h_Fj-DC78JLy3Vgi_jsZ9537E1SfKSknecl-T9Vg2UEUYKyp4kpzEWC8IFf3q0P0nOvd-SuIRIGS2eJyc8z4ssT8lp8vOTkXej9cEouGxbo6Tag21hg24eoPJG9hZ-_aCLShkN1_1e2cnZgGaENe6w99BaB5XeyVGhhrXZoYMr0zjrjQc5alga57o_Way5kcHgGDx8N6GDZefsGI1XOMXzEJELWNphki5KBQu3nQyHqhXKPnR72MzNFlXwH6CCm-gwxSQawibMev8iedbK3uP5QzxLvl5d3i5Xi_WX68_Lar1QKSnDohEC04ZKVXKqOSWZJLnSOSqdlpyJEpkUrMh0llIsNWMas4aUulWiaZhqU36WfLzXneZmQK3ic5zs68mZQbp9baWp_70ZTVff2V1dipxznkWBNw8Czn6b0Yd6MF5h38sR7exrVuSCsawoD16v_0O3dnZjfN6BKhijQtBIvb2nVPwT77B9bIaS-jAl9dGURPrVcf-P7N-Z4L8BJmq8HQ</recordid><startdate>20230116</startdate><enddate>20230116</enddate><creator>Lee, Yoonseok</creator><creator>Bae, Seryun</creator><creator>Kim, Ji Hoon</creator><creator>Kwak, Minjung</creator><creator>Jeon, So Yeon</creator><creator>Kim, Taehyung</creator><creator>Yim, Sun Young</creator><creator>Lee, Young-Sun</creator><creator>Jung, Young Kul</creator><creator>Seo, Yeon Seok</creator><creator>Yim, Hyung Joon</creator><creator>Yeon, Jong Eun</creator><creator>Byun, Kwan Soo</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6396-0859</orcidid><orcidid>https://orcid.org/0000-0002-0510-7371</orcidid><orcidid>https://orcid.org/0000-0002-6566-1382</orcidid><orcidid>https://orcid.org/0000-0002-7747-4293</orcidid><orcidid>https://orcid.org/0000-0001-5493-3592</orcidid><orcidid>https://orcid.org/0000-0001-7346-5974</orcidid><orcidid>https://orcid.org/0000-0003-3924-0434</orcidid></search><sort><creationdate>20230116</creationdate><title>Diagnostic Efficacy of Serum Asialo α1-Acid Glycoprotein Levels for Advanced Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Compared to That in Healthy Subjects: A Prospective Study</title><author>Lee, Yoonseok ; Bae, Seryun ; Kim, Ji Hoon ; Kwak, Minjung ; Jeon, So Yeon ; Kim, Taehyung ; Yim, Sun Young ; Lee, Young-Sun ; Jung, Young Kul ; Seo, Yeon Seok ; Yim, Hyung Joon ; Yeon, Jong Eun ; Byun, Kwan Soo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-b88e4b1ac931d3105a06cd6ecd493289e2a8275d541e9d22de5b09dfc8bb2cf43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Accuracy</topic><topic>Acids</topic><topic>Biomarkers</topic><topic>Biopsy</topic><topic>Clinical medicine</topic><topic>Diabetes</topic><topic>Glycoproteins</topic><topic>Hepatitis B</topic><topic>Hypertension</topic><topic>Laboratories</topic><topic>Liver cancer</topic><topic>Liver cirrhosis</topic><topic>Liver diseases</topic><topic>Patients</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Yoonseok</creatorcontrib><creatorcontrib>Bae, Seryun</creatorcontrib><creatorcontrib>Kim, Ji Hoon</creatorcontrib><creatorcontrib>Kwak, Minjung</creatorcontrib><creatorcontrib>Jeon, So Yeon</creatorcontrib><creatorcontrib>Kim, Taehyung</creatorcontrib><creatorcontrib>Yim, Sun Young</creatorcontrib><creatorcontrib>Lee, Young-Sun</creatorcontrib><creatorcontrib>Jung, Young Kul</creatorcontrib><creatorcontrib>Seo, Yeon Seok</creatorcontrib><creatorcontrib>Yim, Hyung Joon</creatorcontrib><creatorcontrib>Yeon, Jong Eun</creatorcontrib><creatorcontrib>Byun, Kwan Soo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Yoonseok</au><au>Bae, Seryun</au><au>Kim, Ji Hoon</au><au>Kwak, Minjung</au><au>Jeon, So Yeon</au><au>Kim, Taehyung</au><au>Yim, Sun Young</au><au>Lee, Young-Sun</au><au>Jung, Young Kul</au><au>Seo, Yeon Seok</au><au>Yim, Hyung Joon</au><au>Yeon, Jong Eun</au><au>Byun, Kwan Soo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diagnostic Efficacy of Serum Asialo α1-Acid Glycoprotein Levels for Advanced Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Compared to That in Healthy Subjects: A Prospective Study</atitle><jtitle>Journal of clinical medicine</jtitle><addtitle>J Clin Med</addtitle><date>2023-01-16</date><risdate>2023</risdate><volume>12</volume><issue>2</issue><spage>712</spage><pages>712-</pages><issn>2077-0383</issn><eissn>2077-0383</eissn><abstract>Background: Serum asialo α1-acid gycoprotein (AsAGP) is a novel biomarker specific to liver fibrosis. Aim: To evaluate the diagnostic efficacy of serum AsAGP levels in classifying the severity of liver fibrosis and differentiating liver cirrhosis (LC) in patients with chronic hepatitis B (CHB) from healthy controls. Methods: Overall, 206 subjects were prospectively enrolled. LC was diagnosed based on liver stiffness levels (>11 kPa) measured using transient elastography. Serum AsAGP levels were measured using an antibody-lectin sandwich immunoassay. We investigated the diagnostic performance by comparing serum AsAGP levels among healthy control, CHB, and CHB with LC groups. Sensitivity, specificity, and optimal AsAGP cut-off values were also calculated. Results: Serum AsAGP levels were significantly different between healthy controls, CHB patients, and CHB patients with LC (1.04 ± 0.31 µg/mL, 1.12 ± 0.34 µg/mL, 1.51 ± 0.43 µg/mL respectively; p < 0.001). Serum AsAGP levels positively correlated with liver stiffness (r = 0.46, p < 0.001). AUROC of healthy control versus CHB with LC was 0.821 (p < 0.001, optimal cut-off 1.036 µg/mL). AUROC of healthy control versus CHB was 0.624 (p = 0.049, optimal cut-off level 0.934 µg/mL). AUROC of CHB versus CHB with LC was 0.765, (p < 0.001, optimal cut-off 1.260 µg/mL). Conclusions: Serum AsAGP levels in CHB patients with LC were significantly higher than those in healthy controls and CHB patients. AsAGP levels showed good diagnostic performance in predicting advanced fibrosis and cirrhosis, which suggests a potential role as a biomarker for predicting the progression of liver disease in CHB.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>36675640</pmid><doi>10.3390/jcm12020712</doi><orcidid>https://orcid.org/0000-0001-6396-0859</orcidid><orcidid>https://orcid.org/0000-0002-0510-7371</orcidid><orcidid>https://orcid.org/0000-0002-6566-1382</orcidid><orcidid>https://orcid.org/0000-0002-7747-4293</orcidid><orcidid>https://orcid.org/0000-0001-5493-3592</orcidid><orcidid>https://orcid.org/0000-0001-7346-5974</orcidid><orcidid>https://orcid.org/0000-0003-3924-0434</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2077-0383 |
| ispartof | Journal of clinical medicine, 2023-01, Vol.12 (2), p.712 |
| issn | 2077-0383 2077-0383 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9863335 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central |
| subjects | Accuracy Acids Biomarkers Biopsy Clinical medicine Diabetes Glycoproteins Hepatitis B Hypertension Laboratories Liver cancer Liver cirrhosis Liver diseases Patients |
| title | Diagnostic Efficacy of Serum Asialo α1-Acid Glycoprotein Levels for Advanced Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Compared to That in Healthy Subjects: A Prospective Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T14%3A55%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diagnostic%20Efficacy%20of%20Serum%20Asialo%20%CE%B11-Acid%20Glycoprotein%20Levels%20for%20Advanced%20Liver%20Fibrosis%20and%20Cirrhosis%20in%20Patients%20with%20Chronic%20Hepatitis%20B%20Compared%20to%20That%20in%20Healthy%20Subjects:%20A%20Prospective%20Study&rft.jtitle=Journal%20of%20clinical%20medicine&rft.au=Lee,%20Yoonseok&rft.date=2023-01-16&rft.volume=12&rft.issue=2&rft.spage=712&rft.pages=712-&rft.issn=2077-0383&rft.eissn=2077-0383&rft_id=info:doi/10.3390/jcm12020712&rft_dat=%3Cproquest_pubme%3E2767221881%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2767221881&rft_id=info:pmid/36675640&rfr_iscdi=true |